ResMed traded at 32.71 this Monday September 26th, increasing 0.67 or 2.09 percent since the previous trading session. Looking back, over the last four weeks, ResMed gained 2.03 percent. Over the last 12 months, its price fell by 14.64 percent. Looking ahead, we forecast ResMed to be priced at 31.25 by the end of this quarter and at 28.99 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
32.71
Daily Change
2.09%
Yearly
-14.64%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Avita Medical Inc 1.64 -0.07 -4.09% -67.91%
Ansell 24.78 0.02 0.08% -28.73%
Cochlear 200.50 3.94 2.00% -11.54%
CSL 283.60 5.46 1.96% -7.40%
Estia Health 1.96 -0.06 -2.74% -13.88%
Fisher & Paykel Healthcare 17.01 0.21 1.25% -44.77%
Healius Ltd 3.39 0.03 0.89% -32.06%
Integral Diagnostics Ltd 2.53 -0.05 -1.75% -46.39%
Mayne Pharma 0.25 -0.01 -3.85% -15.25%
Nanosonics Ltd 3.49 0.07 2.05% -45.89%
Opthea Ltd 1.14 -0.01 -0.44% -16.85%
Polynovo Ltd 1.43 0.03 1.79% -27.48%
Regis Healthcare Ltd 1.72 -0.03 -1.44% -17.15%
Ramsay Health Care 58.46 -2.07 -3.42% -15.62%
ResMed 32.71 0.67 2.09% -14.64%
Sonic Healthcare 30.09 0.42 1.42% -26.91%
Sigma Healthcare Ltd 0.65 -0.05 -7.14% 9.24%
Telix Pharmaceuticals Ltd 5.28 -0.03 -0.57% -12.73%

Indexes Price Day Year
AU200 6485 -89.43 -1.36% -12.17%
AUALL 6686 -102.80 -1.51% -13.07%

ResMed
ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep apnea, chronic obstructive pulmonary disease (COPD), neuromuscular disease and other chronic diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions.